These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 22253690)
1. Modeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug design. Panigrahi S; Stetefeld J; Jangamreddy JR; Mandal S; Mandal SK; Los M PLoS One; 2012; 7(1):e28395. PubMed ID: 22253690 [TBL] [Abstract][Full Text] [Related]
2. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. Salgia R; Pisick E; Sattler M; Li JL; Uemura N; Wong WK; Burky SA; Hirai H; Chen LB; Griffin JD J Biol Chem; 1996 Oct; 271(41):25198-203. PubMed ID: 8810278 [TBL] [Abstract][Full Text] [Related]
3. Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Sattler M; Salgia R Leukemia; 1998 May; 12(5):637-44. PubMed ID: 9593259 [TBL] [Abstract][Full Text] [Related]
4. Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. Kardinal C; Konkol B; Schulz A; Posern G; Lin H; Adermann K; Eulitz M; Estrov Z; Talpaz M; Arlinghaus RB; Feller SM FASEB J; 2000 Aug; 14(11):1529-38. PubMed ID: 10928987 [TBL] [Abstract][Full Text] [Related]
5. Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signaling complex. Gregor T; Bosakova MK; Nita A; Abraham SP; Fafilek B; Cernohorsky NH; Rynes J; Foldynova-Trantirkova S; Zackova D; Mayer J; Trantirek L; Krejci P Cell Mol Life Sci; 2020 Oct; 77(19):3885-3903. PubMed ID: 31820037 [TBL] [Abstract][Full Text] [Related]
6. CRKL binding to BCR-ABL and BCR-ABL transformation. Kolibaba KS; Bhat A; Heaney C; Oda T; Druker BJ Leuk Lymphoma; 1999 Mar; 33(1-2):119-26. PubMed ID: 10194128 [TBL] [Abstract][Full Text] [Related]
7. Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Heaney C; Kolibaba K; Bhat A; Oda T; Ohno S; Fanning S; Druker BJ Blood; 1997 Jan; 89(1):297-306. PubMed ID: 8978305 [TBL] [Abstract][Full Text] [Related]
8. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins. Uemura N; Salgia R; Li JL; Pisick E; Sattler M; Griffin JD Leukemia; 1997 Mar; 11(3):376-85. PubMed ID: 9067577 [TBL] [Abstract][Full Text] [Related]
9. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells. Grumbach IM; Mayer IA; Uddin S; Lekmine F; Majchrzak B; Yamauchi H; Fujita S; Druker B; Fish EN; Platanias LC Br J Haematol; 2001 Feb; 112(2):327-36. PubMed ID: 11167825 [TBL] [Abstract][Full Text] [Related]
10. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site. de Jong R; ten Hoeve J; Heisterkamp N; Groffen J Oncogene; 1997 Feb; 14(5):507-13. PubMed ID: 9053848 [TBL] [Abstract][Full Text] [Related]
11. Purification and molecular cloning of SH2- and SH3-containing inositol polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, erythropoietin, and Bcr-Abl. Odai H; Sasaki K; Iwamatsu A; Nakamoto T; Ueno H; Yamagata T; Mitani K; Yazaki Y; Hirai H Blood; 1997 Apr; 89(8):2745-56. PubMed ID: 9108392 [TBL] [Abstract][Full Text] [Related]